Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.61 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 12/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 8/20 | 0.50 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.41 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 3/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium Ion SCHEMBL28738648 | 0.93 | PTPN11 (0.54) | PTPN11PTPN1CA2MAPK1SMN1; SMN2 | |
| SCHEMBL216185 | 0.78 | PTPN1 (0.62) | PTPN11PTPN1CA2MAPK1SMN1; SMN2 | |
| SCHEMBL27514473 | 0.78 | KDM1A (0.59) | PTPN11PTPN1CA2MAPK1SMN1; SMN2 | |
| SCHEMBL1419244 | 0.77 | CA2 (0.53) | PTPN11PTPN1CA2MAPK1SMN1; SMN2 | |
| SCHEMBL1976973 | 0.77 | PTPN1 (0.60) | PTPN11PTPN1CA2MAPK1SMN1; SMN2 | |
| SCHEMBL7527132 | 0.77 | PTPN1 (0.66) | PTPN11PTPN1CA2MAPK1SMN1; SMN2 | |
| SCHEMBL28665290 | 0.77 | PTPN1 (0.60) | PTPN11PTPN1CA2MAPK1SMN1; SMN2 | |
| SCHEMBL7528321 | 0.76 | PTPN11 (0.79) | PTPN11PTPN1CA2MAPK1SMN1; SMN2 | |
| SCHEMBL20526154 | 0.76 | PTPN11 (0.49) | PTPN11PTPN1CA2MAPK1SMN1; SMN2 | |
| SCHEMBL6232580 | 0.76 | PTPN11 (0.34) | PTPN11PTPN1CA2MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024146922-A1 | C5AR1 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID | DOMPE' FARMACEUTICI SPA (IT) | 2024-07-11 | — | — | WO | claimed |
| EP-4397306-A1 | C5AR1 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID | Dompe' Farmaceutici S.P.A. (IT) | 2024-07-10 | — | — | EP | claimed |
| US-20240180888-A1 | C5AR1 INHIBITORS FOR TREATING HYPERSENSITIVITY REACTIONS TO TAXANES | DOMPE' FARMACEUTICI SPA (IT) | 2024-06-06 | — | — | US | claimed |
| EP-4308114-A1 | C5AR1 INHIBITORS FOR TREATING HYPERSENSITIVITY REACTIONS TO TAXANES | Dompe' Farmaceutici SpA (IT) | 2024-01-24 | — | — | EP | claimed |
| CN-117337176-A | C5AR1 inhibitors for treating hypersensitivity to taxanes | 东佩制药股份公司 | 2024-01-02 | — | — | CN | claimed |
| US-20200397725-A1 | C5AR INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED IATROGENIC PAIN | DOMPE' FARMACEUTICI S.P.A. (IT) | 2020-12-24 | — | — | US | claimed |
| EP-3723744-A2 | C5AR INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED IATROGENIC PAIN | Dompé farmaceutici S.p.A. (IT) | 2020-10-21 | — | — | EP | claimed |
| CN-111511363-A | C5aR inhibitors for the treatment of chemotherapy-induced iatrogenic pain | 多姆皮制药公司 | 2020-08-07 | — | — | CN | claimed |
| WO-2019115493-A2 | C5AR INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED IATROGENIC PAIN | DOMPE' FARMACEUTICI S.P.A. (IT) | 2019-06-20 | — | — | WO | claimed |
| EP-3498269-A1 | C5AR INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED IATROGENIC PAIN | Dompé farmaceutici S.p.A. (IT) | 2019-06-19 | — | — | EP | claimed |
| WO-2007060215-A2 | (R)-ARYLKYLAMINO DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' PHA.R.MA S.P.A. (IT) | 2007-05-31 | — | — | WO | claimed |
| CN-1882530-A | Amidines and derivatives thereof and pharmaceutical compositions containing them | DOMPE PHA R MA SPA RES & MFG (IT) | 2006-12-20 | — | — | CN | claimed |
| US-20060258730-A1 | Sulfonic acids, their derivatives and pharmaceutical compositions containing them | DOMPE S.P.A. (IT) | 2006-11-16 | — | — | US | claimed |
| EP-1606248-A2 | SULFONIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dompé S.P.A. (IT) | 2005-12-21 | — | — | EP | claimed |
| EP-1565430-A1 | BIGUANIDE AND DIHYDROTRIAZINE DERIVATIVES | JACOBUS PHARMACEUTICAL CO. INC. (US) | 2005-08-24 | — | — | EP | claimed |
| WO-2004080951-A2 | SULFONIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE S.P.A. (IT) | 2004-09-23 | — | — | WO | claimed |
| EP-1457485-A1 | Sulfonic acids, their derivatives and pharmaceutical compositions containing them | Dompé S.P.A. (IT) | 2004-09-15 | — | — | EP | claimed |
| US-20040116428-A1 | Biguanide and dihydrotriazine derivatives | JACOBUS PHARMACEUTICAL COMPANY, INC. | 2004-06-17 | — | — | US | claimed |
| WO-2004048320-A1 | BIGUANIDE AND DIHYDROTRIAZINE DERIVATIVES | JACOBUS PHARMACEUTICAL COMPANY, INC. (US) | 2004-06-10 | — | — | WO | claimed |
| US-6403633-B2 | USEFUL ANTIANGIOGENIC, ANTIARTHRITIC, ANTIINFLAMMATORY, ANTIRESTENOTIC, ANTIINVASIVE, ANTIMETASTIC, ANTIOSTEOPOROTIC, ANTIRETINOPATHIC, CONTRACEPTIVE AND TUMORISTATIC TREATMENT AGENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-06-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180888-A1 | C5AR1 INHIBITORS FOR TREATING HYPERSENSITIVITY REACTIONS TO TAXANES | C5AR1, C5AR2, C3AR1 | PTPN11 3417/4885PTPN1 3009/4885CA2 3909/4885 |
| US-20200397725-A1 | C5AR INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED IATROGENIC PAIN | C5AR2, C5AR1, C3AR1 | PTPN11 1610/4885PTPN1 2498/4885CA2 1317/4885 |
| US-20060258730-A1 | Sulfonic acids, their derivatives and pharmaceutical compositions containing them | CCR8, CCR1, CXCR1 | PTPN11 127/4885PTPN1 115/4885CA2 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.